23314-57-0 Usage
Description
Triarachidonin, the triacylglycerol derivative of Arachidonic Acid (A765000), is a bioactive compound that has been found to exhibit various physiological effects. It plays a significant role in the synthesis of prostaglandins and has been shown to inhibit the hepatic stearoyl-CoA desaturase-1 gene in diabetic mice.
Uses
Used in Pharmaceutical Applications:
Triarachidonin is used as a bioactive compound for stimulating prostaglandin synthesis in the kidney in a dose-dependent manner. This makes it a potential candidate for the development of pharmaceuticals targeting kidney-related conditions.
Used in Diabetes Management:
Triarachidonin is used as a therapeutic agent for inhibiting the hepatic stearoyl-CoA desaturase-1 gene in diabetic mice. This application suggests its potential use in the development of treatments for diabetes and related metabolic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 23314-57-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,3,1 and 4 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 23314-57:
(7*2)+(6*3)+(5*3)+(4*1)+(3*4)+(2*5)+(1*7)=80
80 % 10 = 0
So 23314-57-0 is a valid CAS Registry Number.
InChI:InChI=1/C63H98O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-52-55-61(64)67-58-60(69-63(66)57-54-51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)59-68-62(65)56-53-50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h16-21,25-30,34-39,43-48,60H,4-15,22-24,31-33,40-42,49-59H2,1-3H3/b19-16+,20-17+,21-18+,28-25+,29-26+,30-27+,37-34+,38-35+,39-36+,46-43+,47-44+,48-45+
23314-57-0Relevant articles and documents
TREATMENT OF NEURODEGENERATIVE CONDITIONS
-
Page/Page column 33-34, (2008/06/13)
A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.
